<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink">
  <front>
    <journal-meta />
    <article-meta>
      <title-group>
        <article-title>Blood glucose levels regulation in a healthy and in a diabetic person modelled with Petri Nets.</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <string-name>Kamila Barylska</string-name>
          <xref ref-type="aff" rid="aff0">0</xref>
        </contrib>
        <contrib contrib-type="author">
          <string-name>Anna Gogolińska</string-name>
          <xref ref-type="aff" rid="aff0">0</xref>
        </contrib>
        <aff id="aff0">
          <label>0</label>
          <institution>Nicolaus Copernicus University in Toruń</institution>
        </aff>
      </contrib-group>
      <abstract>
        <p>A healthy person's body automatically maintains normoglycemia, i.e. the proper level of sugar in the blood. Insulin and glucagon are pancreatic hormones of key importance for the regulation of energy metabolism and blood glucose concentration. They work in opposite ways - the role of insulin is to prevent hyperglycemia, while glucagon plays a diferent role - it prevents hypoglycemia. In a person with diabetes, the above process is impaired (or does not work at all). Therefore, external mechanisms for achieving the proper blood sugar level are necessary, for the most part, administering exogenous insulin. In the paper we present an elementary Petri net model of normoglycemia maintaining in a healthy person, and a basic model of the processes occurring in the body of a person sufering from diabetes. Comparison and analysis of both models allows for a better understanding of the mechanisms operating in the (healthy and sick) human body. Such an exploration also makes it possible to better adapt the treatment to a sick person and constitutes the initial step on the way to our long-time goal to create the whole body model of the glucose regulation in a healthy human and a person with diabetes.</p>
      </abstract>
      <kwd-group>
        <kwd>eol&gt;diabetes</kwd>
        <kwd>normoglycemia</kwd>
        <kwd>bioinformatics</kwd>
        <kwd>Petri nets</kwd>
        <kwd>modelling</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec id="sec-1">
      <title>1. Introduction</title>
      <p>
        The body of a healthy person strives to maintain normoglycemia, i.e. the appropriate level of sugar in the
blood. According to the World Health Organization [
        <xref ref-type="bibr" rid="ref24">24</xref>
        ] and the American Diabetes Association [
        <xref ref-type="bibr" rid="ref26">26</xref>
        ], the
expected values for normal fasting blood glucose concentration are between 70/ (3.9/)
and 100/ (5.6/), while two hours after eating the levels should be up to 140/.
      </p>
      <p>
        Diabetes is a chronic disease that occurs either when the pancreas does not produce enough insulin
(a hormone that regulates blood glucose) or when the body cannot efectively use the insulin it produces.
There are three main types of diabetes: type 1, type 2, and gestational diabetes (diabetes while pregnant).
Type 1 diabetes is a condition in which the immune system destroys insulin-making cells (beta cells)
in the human pancreas. That means that the body cannot produce either enough endogenous insulin,
or none at all. Type 2 diabetes is a chronic condition that happens when high blood sugar levels
(hyperglycemia) persist in a body. It happens when pancreas is not able to produce enough insulin,
body does not use insulin properly, or both. For people with diabetes, blood sugar level targets are as
follows [
        <xref ref-type="bibr" rid="ref25">25</xref>
        ]:
• before meals : 72 to 126/ (4 to 7/) for people with type 1 or type 2 diabetes
• after meals : under 162/ (9/) for people with type 1 diabetes and under 153/
(8.5/) for people with type 2 diabetes
In case of diabetes, the body’s spontaneous pursuit of normoglycemia is very dificult or even impossible,
and it must be moderated from the outside.
      </p>
      <p>
        Diabetes is considered one of the civilization diseases. According to the International Diabetes
Federation data for 2021 [
        <xref ref-type="bibr" rid="ref20">20</xref>
        ] and the IDF Diabetes Atlas [
        <xref ref-type="bibr" rid="ref19">19</xref>
        ], one in ten people in the world, that is,
approximately, 537 million adults (20-79 years), are living with diabetes. The total number of people
living with diabetes is projected to rise to 643 million by 2030 and 783 million by 2045. It is estimated
that 6.7 million adults died from diabetes or its complications in 2021, which means one death every 5
seconds. Diabetes was responsible for at least $966 billion in health expenditure in 2021, which is 9% of
the global total spent on healthcare.
      </p>
      <p>It is therefore not surprising, that in many fields of science, intensive work has being undertaken
not only to cure the disease, but also, and perhaps above all, to prevent or delay its future health
complications (such as heart disease, chronic kidney disease, nerve damage, and other problems with
feet, oral health, vision, hearing, and mental health) or improving the quality of life of patients and
their families.</p>
      <p>
        More and more advanced systems are being developed to continuously measure blood glucose
levels without the need to puncture the skin (CGM - continuous glucose monitoring [
        <xref ref-type="bibr" rid="ref2 ref6">6, 2</xref>
        ]), the insulin
pump industry has been developing rapidly. Closed loop systems (so called artificial pancreas ), enabling
automatic insulin delivery by the pump, were also created and operate successfully, both as a commercial
solution (MiniMed 780G System [
        <xref ref-type="bibr" rid="ref22">22</xref>
        ], Tandem Tslim Control IQ [
        <xref ref-type="bibr" rid="ref23">23</xref>
        ], CamAPS FX [
        <xref ref-type="bibr" rid="ref18">18</xref>
        ], a.o.), or developed
on a DIY basis (AAPS [
        <xref ref-type="bibr" rid="ref17">17</xref>
        ], Loop [
        <xref ref-type="bibr" rid="ref21">21</xref>
        ], a.o.). Countless applications are being developed for diabetics
and their families, as well as health care professionals, such as bolus calculators, applications for
counting food nutritional value, diabetes management, statistics and many others. Intensive work is
also underway on the use of artificial intelligence in this field [
        <xref ref-type="bibr" rid="ref10 ref12 ref5">12, 10, 5</xref>
        ]. However, we have noticed that
most non-medical solutions focus on solving a particular problem without ofering a broader view of
diabetes. On the other hand, medical papers usually focus on one single element of the whole process
of glucose regulation for healthy and diabetic people. Therefore, there exists a great need for a more
holistic approach, which recently becomes more and more popular.
      </p>
      <p>Our long-term goal is to create a simple and intuitive mathematical model representing the glucose
regulation mechanisms occurring in the body of a healthy person and a person with diabetes. This model
should be easily analysable and clear, but at the same time, capable of representing complex processes
consisting of interactions between many components. In our opinion, Petri nets (PNs) constitute a perfect
tool for this purpose. Due to PNs intuitive graphical representation and mathematical properties, the
model would be useful for people with and without medical background. This could allow for a better
understanding of the processes occurring in a human body, predicting new therapeutic targets and
designing drug therapies. We are aware, that our goal (modelling the entire process) is ambitious and
would not be reached at once. Hence, our preliminary step, presented below, is to model processes of
achieving normoglycemia in the case of a healthy or sufering from diabetes person.</p>
      <p>In this paper, we present an elementary model of the glucose level regulating processes in a healthy
body, as well as very basic model of processes taking place in the body of a sick person, aiming to
achieve normoglycemia. We believe that the analysis of both models may be of great importance for
understanding the processes taking place in a healthy body and disease of diabetes and shows how
complicated the process of maintaining the appropriate sugar level may be. Such knowledge may allow
for appropriate adjustment of therapy to a given person.</p>
      <p>We use standard Petri net analysis tools, such as the reachability graph and t-invariants, to study out
models. In the following section, we recall the basic concepts of Petri nets, and in subsequent parts of
the paper we introduce and discuss Petri nets models of glucose levels regulating processes in a healthy
and diabetic person. The paper ends with a summary and future plans.</p>
    </sec>
    <sec id="sec-2">
      <title>2. Preliminaries</title>
      <p>
        In this section we recall the basic notions concerning Petri Nets and its properties [
        <xref ref-type="bibr" rid="ref13 ref14 ref4 ref9">4, 9, 13, 14</xref>
        ].
      </p>
      <p>A finite labelled transition system with initial state is a tuple   = (, →, , 0) with nodes  (a finite
set of states), edge labels  (a finite set of letters), edges → ⊆ ( ×  × ), and an initial state 0 ∈ .
A label  is enabled at  ∈ , denoted by [⟩, if ∃′ ∈  : (, , ′) ∈ →. A state ′ is reachable from 
through the execution of  ∈  * , denoted by [ ⟩′, if there is a directed path from  to ′ whose edges
are labelled consecutively by  . The set of states reachable from  is denoted by [⟩. A sequence  ∈  *
is allowed, or firable, from a state , denoted by [ ⟩, if there is some state ′ such that [ ⟩′.</p>
      <p>An (initially marked) Petri net (PN) is denoted as  = (, , , 0) where  is a finite set of places,
 is a finite set of transitions,  is the flow function  : (( ×  ) ∪ ( ×  )) → N specifying the
arc weights, and 0 is the initial marking (where a marking is a mapping  :  → N, indicating the
number of tokens in each place). A transition  ∈  is enabled at a marking  , denoted by  [⟩,
if ∀ ∈  :  () ≥  (, ). The firing of  leads from  to  ′, denoted by  [⟩ ′, if  [⟩ and
 ′() =  () −  (, ) +  (, ). This can be extended, as usual, to  [ ⟩ ′ for sequences  ∈  * ,
and [ ⟩ denotes the set of markings reachable from  . We call a marking  deadlock if it does not
enable any transition, i.e. for every  ∈  we have ∃ ∈  :  () &lt;  (, ). The reachability graph
( ) of a bounded (such that the number of tokens in each place does not exceed a certain finite
number) Petri net  is the labelled transition system with the set of vertices [0⟩, initial state 0,
label set  , and set of edges {(, ,  ′) | ,  ′ ∈ [0⟩ ∧  [⟩ ′}.</p>
      <p>0</p>
      <p>Note that the reachability graph of a bounded Petri net captures the exact information about the
reachable markings of the net, and therefore reflects the entire behaviour of a given net. Figure 2 depicts
an exemplary Petri net, together with its reachability graph.</p>
      <p>
        Let  ∈  ∪  , ∙  = { ∈ ( ∪  ) |  (, ) &gt; 0} and ∙ = { ∈ ( ∪  ) |  (, ) &gt; 0}.
A Petri net  = (, , , 0) can be represented in the form of matrices with integer coeficients:
an input matrix, an output matrix and an incidence matrix [
        <xref ref-type="bibr" rid="ref13">13</xref>
        ]. Assume that # = , # = . The
input matrix is a matrix + = (, )× , where , = 1 if  ∈ ∙ or , = 0 if  ∈/ ∙ . The output
matrix is a matrix − = (, )× , where , = 1 if  ∈∙  or , = 0 if  ∈/∙  . The incidence
matrix is a matrix  = (, )×  where  = + − − . T-invariant is a vector  ∈ N satisfying
 *  = 0. The t-invariant contains transitions of the PN and firing all transitions from one t-invariant
will reproduce a given marking before firing of transitions. This property follows directly from the
definition.
      </p>
      <p>An inhibitor net is a quintuple S = (, , , , 0), where: (, , , 0) is a Petri net, as defined
above;  ⊆  ×  is the set of inhibitor arcs (depicted by edges ended with a small empty circle). The
set of inhibitor entries to  is denoted by ∘  = { ∈  | (, ) ∈ }. A transition  ∈  (of an inhibitor
net) is enabled in a marking  whenever ∙  ≤  (all its entries are marked) and (∀ ∈ ∘ )  () = 0,
i.e. all inhibitor entries to  are empty. The execution of  leads to the same marking as in the ordinary
Petri nets case.</p>
    </sec>
    <sec id="sec-3">
      <title>3. Models</title>
      <sec id="sec-3-1">
        <title>3.1. Healthy</title>
        <p>two hours after eating. A token located in one of places H, N, L informs that the concentration of
glucose is in the corresponding level. That level can be afected in a couple of ways.</p>
        <p>The body tries to maintain the normal level of glucose. However, glucose is the main source of energy
in the body, and every life process consumes it while occurring. It results in a decrease of the amount
of glucose. The low concentration of glucose (place L) causes the hunger feeling and the desire to eat.
After eating, which is represented by eating transition, the carbohydrates are available for the organism,
what is pictured in place Carb. In such a situation, clearly, the level of glucose increases to the normal
or high level (transitions t3 and t2, respectively). However, the level of glucose is not only an efect of
its delivery and consumption. The organism is not a passive observer of these processes, but actively
participates in the glucose regulation, since the abnormal level of glucose is not desirable because
it negatively afects the whole organism. The most important organ in the regulation process is the
pancreas, represented by Pancreas place. Stimulated by the high level of glucose, the pancreas produces
insulin, which is represented by transition t1. The presence of insulin is modelled by place Insulin.
Insulin induces processes (transition t4) which result in reduction of the level of glucose and storage of
it in various organs - place Storage, mostly liver and fat tissue.</p>
        <p>
          On the other hand, when the level of glucose is low, the pancreas produces glucagon, which is
represented by transition t0 and place Glucagon, visualising the presence of that hormone. Opposite to
insulin, glucagon stimulates processes (transition t5), aiming to release the stored substances from the
liver and fat tissue (place Storage) and increase the level of glucose. Our PN model of processes taking
place in the liver, related to storing and releasing of glucose in the presence of insulin and glucagon, is
presented in [
          <xref ref-type="bibr" rid="ref1">1</xref>
          ].
        </p>
        <p>To compute the reachability graph the PN needs to be bounded. The model presented in Figure 2 is
not bounded, because when place L is marked transition eating can produce an unlimited number of
tokens. However, such a situation is not possible in the real organism (infinitive eating and at the same
time low level of glucose). In order to compute the reachability graph of the model, we removed the
eating transition and assumed that only one instance of carbohydrates is available. It would correspond
to the situation of the glucose regulation processes after one meal and before the next one. The initial
marking used to compute the reachability graph is depicted in Figure 2. The obtained graph is presented
in Figure 3.</p>
        <p>While analysing the reachability graph of the PN model one can notice that the model tends to
the state with place N marked. From the initial state, the state N|Pancreas|Storage can be reached by
three diferent paths of transitions executions. From that state (and by two side paths) executions of
transitions lead to state N|Pancreas. Notice that all those paths are related to maintaining the normal
level of glucose (token in place N ) by using available glucose sources, like carbohydrates (place Carb) and
substances stored by the body (place Storage). After state N|Pancreas the deadlock marking L|Pancreas
is reached, which corresponds to the situation where all available sources of glucose are used and the
next meal is necessary.</p>
        <p>The dynamic of the model is nicely captured by t-invariants present in the model. The PN model has
only two t-invariants. The first contains transitions: eating, life, t3 and is depicted green in Figure 3.
The second contains transitions: eating, life, t0, t1, t2, t4, t5 and is depicted blue in Figure 3. It is
obvious that the PN model is covered by t-invariants. The first t-invariant corresponds to the process
of glucose regulation related only to processes of glucose consumption and providing. Like it was
mentioned above, the organism is not a passive observer of these processes, but actively participates in
the glucose regulation. Those regulation mechanisms are represented by transitions included in the
second t-invariant. By the definition of t-invariant, when the model starts with place N marked like in
the initial marking, the execution of all transitions from the t-invariant will lead to the same, initial
marking. Hence, firing the transitions corresponding to the glucose level regulation mechanisms of the
body, included in the second t-invariant, would result in maintaining the normal level of glucose (token
back in place N ).</p>
      </sec>
      <sec id="sec-3-2">
        <title>3.2. Unhealthy</title>
        <p>
          Now let us look at Figure 4, which depicts how the issue of the glucose level regulation looks like in a
person sufering from diabetes. The model contains 13 places and 27 transitions. For clarity, we have
decided to use inhibitor arcs in this model, which, however, could be eliminated (in accordance with [
          <xref ref-type="bibr" rid="ref11">11</xref>
          ]).
Similarly to the previous model, places H, N and L represents the levels of glucose (respectively):
elevated (high), normal and low, but this time we apply guidelines for sick people, i.e. before meals:
72 to 126/ (4 to 7/) for people with type 1 or type 2 diabetes, and after meals: under
162/ (9/) for people with type 1 diabetes and under 153/ (8.5/) for people
with type 2 diabetes.
        </p>
        <p>
          In a healthy organism the body produces the suitable amount of insulin in the suitable time. In contrast
to that, in a diabetic case, insulin is administrated from the outside and a diabetic person does not know
their exact level of insulin. Because of that, three possible levels of insulin are present in the model: low
(place LI ), normal (place NI - in a healthy body it is the only one possible) and high (place HI ). Only
the level of glucose can be checked and based on that, in the ideal case, the suitable amount of insulin
is administrated. Moreover, in a diabetic organism the internal mechanisms of glucose regulation do
not work correctly, and even when the person is doing everything correctly by calculating the amount
of eaten carbohydrates and corresponding dose of insulin, low or high glucose levels are still possible
([
          <xref ref-type="bibr" rid="ref3 ref8">8, 3</xref>
          ]). Such ambiguity is caused by changes that occur in the body and of which the person is not
aware (because they cannot be monitored on an ongoing basis) and depends, among others, on physical
activity, the state of the hormonal and digestive systems, as well as technical issues such as the quality
of the injection or insulin age. This uncertainty is represented in our diabetic PN model. Due to the
fact that we cannot predict or (more importantly) monitor many of the causes of inappropriate blood
glucose levels, in our model we focus on the amounts of eaten carbohydrates and administrated insulin,
and interactions between them.
        </p>
        <p>Transition PIns corresponds to the administration of insulin, which is represented by place Ins. When
insulin is provided, it may (or may not if the amount is not suficient) afect the current level of insulin in
the body. This is represented by transitions I1 to I5. When insulin is provided (place InsActive), it can be
used by the body to reduce (little or much) the level of glucose - transitions D1 to D6. Still, the efect of
insulin supply can be not suficient and the level of glucose could not change. When carbohydrates are
eaten (transition PCarb and place Carb), the level of glucose may rise or may not be changed, because
of the presence of insulin in the blood. Insulin, during that process, is used by cells, hence its level may
be reduced. Transitions from U1 to U7 represent the change of glucose level. Transitions from Ch1 to
Ch5, To, From and From2 are responsible for managing the level of insulin.</p>
        <p>
          One can easily notice, that the dynamic of the PN diabetic model is much less certain, and in contrast
to the healthy model, it is not possible to predict the exact result of transitions executions. To calculate
the reachability graph, similarly like for the healthy PN model, transitions PIns and PCarb were removed,
and the initial marking was the one obtained after executions of those transitions once (place Carb
and Ins marked with one token). It represents the situation after the meal and the administration of
insulin. Places NI and N, like in Figure 4, were also marked with one token each. Moreover, inhibitor
arcs were removed according to the procedure described in [
          <xref ref-type="bibr" rid="ref11">11</xref>
          ]. The obtained reachability graph is
presented in Figure 5. Even a cursory comparison of both models and graphs shows that in the case of a
person with diabetes, the external mechanisms of glucose levels regulation do not necessarily produce
the desired results. In the reachability graph it is dificult to see the desire to maintain normoglycemia,
like in the healthy case. In general, it is dificult to observe the tendency towards any designated state.
The graph is also much more complicated. From each state there are many possible paths of transitions
executions, which lead to diferent intermediate and final states. The graph shows that the prediction
of glucose level in the diabetic PN model, the same like for a diabetic person in real life, is much more
uncertain and complex.
        </p>
      </sec>
    </sec>
    <sec id="sec-4">
      <title>4. Conclusions and Future Work</title>
      <p>In the paper we have presented the basic Petri net models of normoglycemia maintaining in a healthy
person, and a person sufering from diabetes. We believe that the analysis and comparison of both
models and their reachability graphs could facilitate the understanding of the entire process, which
can be especially useful for a diabetic person. These models can also be used in diabetes education (for
instance, with the use a Petri Net simulation displaying the token game), both for sick people and their
families, as well as for people involved in medicine and health care.</p>
      <p>The presented PN model of the healthy mechanism of glucose regulation seems to be very simple.
However, its dynamic is very interesting and could be a source of basic knowledge about glucose
regulation. Despite its simplicity, the analysis of the model shows the tendency to maintains normoglycemia.
On the other hand, the diabetic PN model shows the much more complex dynamic and the dificulties
in obtaining the desired normal level of glucose.</p>
      <p>The paper constitutes a preliminary step towards designing a complete model visualizing the
regulation of glucose levels in the body, which would aim to better understand the processes occurring in the
body of a healthy person, as well as a person sufering from diabetes.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <ref id="ref1">
        <mixed-citation>
          [1]
          <string-name>
            <surname>Barylska</surname>
            <given-names>K.</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Gogolińska</surname>
            <given-names>A.</given-names>
          </string-name>
          ,
          <article-title>Petri nets in modelling glucose regulating processes in the liver</article-title>
          , submitted to PNSE'
          <volume>24</volume>
          ,
          <year>2024</year>
          .
        </mixed-citation>
      </ref>
      <ref id="ref2">
        <mixed-citation>
          [2]
          <string-name>
            <surname>Battelino</surname>
            <given-names>T.</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Alexander</surname>
            <given-names>C.M.</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Amiel</surname>
            <given-names>S.A.</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Arreaza-Rubin</surname>
            <given-names>G.</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Beck</surname>
            <given-names>R.W.</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Bergenstal</surname>
            <given-names>R.M.</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Buckingham</surname>
            <given-names>B.A.</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Carroll</surname>
            <given-names>J.</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Ceriello</surname>
            <given-names>A</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Chow</surname>
            <given-names>E.</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Choudhary</surname>
            <given-names>P.</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Close</surname>
            <given-names>K.</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Danne</surname>
            <given-names>T.</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Dutta</surname>
            <given-names>S.</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Gabbay</surname>
            <given-names>R.</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Garg</surname>
            <given-names>S.</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Heverly</surname>
            <given-names>J.</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Hirsch</surname>
            <given-names>I.B.</given-names>
          </string-name>
          , Kader t.,
          <string-name>
            <surname>Kenney</surname>
            <given-names>J.</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Kovatchev</surname>
            <given-names>B.</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Lafel</surname>
            <given-names>L.</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Maahs</surname>
            <given-names>D.</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Mathieu</surname>
            <given-names>C.</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Mauricio</surname>
            <given-names>D.</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Nimri</surname>
            <given-names>R.</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Nishimura</surname>
            <given-names>R.</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Scharf</surname>
            <given-names>M.</given-names>
          </string-name>
          ,
          <string-name>
            <given-names>Del Prato S.</given-names>
            ,
            <surname>Renard</surname>
          </string-name>
          <string-name>
            <given-names>E.</given-names>
            ,
            <surname>Rosenstock</surname>
          </string-name>
          <string-name>
            <given-names>J.</given-names>
            ,
            <surname>Saboo</surname>
          </string-name>
          <string-name>
            <given-names>B.</given-names>
            ,
            <surname>Ueki</surname>
          </string-name>
          <string-name>
            <given-names>K.</given-names>
            ,
            <surname>Umpierrez</surname>
          </string-name>
          <string-name>
            <given-names>G.E.</given-names>
            ,
            <surname>Weinzimer</surname>
          </string-name>
          <string-name>
            <given-names>S.A.</given-names>
            ,
            <surname>Phillip</surname>
          </string-name>
          <string-name>
            <surname>M.:</surname>
          </string-name>
          <article-title>Continuous glucose monitoring and metrics for clinical trials: an international consensus statement</article-title>
          ,
          <source>The Lancet Diabetes &amp; Endocrinology</source>
          ,
          <year>2023</year>
          .
        </mixed-citation>
      </ref>
      <ref id="ref3">
        <mixed-citation>
          [3]
          <string-name>
            <surname>DeFronzo</surname>
            <given-names>R. A.</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Ferrannini</surname>
            <given-names>E.</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Zimmet</surname>
            <given-names>P.</given-names>
          </string-name>
          , Alberti G.
          <source>International Textbook of Diabetes Mellitus, 2 Volume Set, 4th Edition</source>
          .
          <year>2015</year>
          .
        </mixed-citation>
      </ref>
      <ref id="ref4">
        <mixed-citation>
          [4]
          <string-name>
            <surname>Desel</surname>
            <given-names>J</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Reisig</surname>
            <given-names>W.</given-names>
          </string-name>
          :
          <article-title>Place or Transition Petri Nets</article-title>
          ,
          <source>Lectures on Petri Nets</source>
          , Vol. I: Basic Models,
          <source>Advances in Petri Nets</source>
          ,
          <volume>1491</volume>
          ,
          <year>1998</year>
          .
        </mixed-citation>
      </ref>
      <ref id="ref5">
        <mixed-citation>
          [5]
          <string-name>
            <surname>Jin</surname>
            <given-names>X.</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Cai</surname>
            <given-names>A.</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Xu</surname>
            <given-names>T.</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Zhang</surname>
            <given-names>X.</given-names>
          </string-name>
          :
          <article-title>Artificial intelligence biosensors for continuous glucose monitoring</article-title>
          ,
          <source>Interdisciplinary Materials</source>
          ,
          <year>2023</year>
          .
        </mixed-citation>
      </ref>
      <ref id="ref6">
        <mixed-citation>
          [6]
          <string-name>
            <surname>Lee</surname>
            <given-names>I.</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Probst</surname>
            <given-names>D.</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Klonof</surname>
            <given-names>D.</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Sode</surname>
            <given-names>K.</given-names>
          </string-name>
          :
          <article-title>Continuous glucose monitoring systems - Current status and future perspectives of the flagship technologies in biosensor research</article-title>
          ,
          <source>Biosensors and Bioelectronics</source>
          ,
          <year>2021</year>
          .
        </mixed-citation>
      </ref>
      <ref id="ref7">
        <mixed-citation>
          [7]
          <string-name>
            <surname>Liu</surname>
            <given-names>GY.</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Barkaoui</surname>
            <given-names>K.</given-names>
          </string-name>
          :
          <article-title>A survey of siphons in Petri nets</article-title>
          .
          <source>Information Sciences 363</source>
          .
          <year>2016</year>
          .
        </mixed-citation>
      </ref>
      <ref id="ref8">
        <mixed-citation>
          [8]
          <string-name>
            <surname>Majkowska</surname>
            <given-names>L.</given-names>
          </string-name>
          :
          <article-title>Podstawy diabetologii dla studentów medycyny i lekarzy praktykóow</article-title>
          .
          <year>2016</year>
          .
        </mixed-citation>
      </ref>
      <ref id="ref9">
        <mixed-citation>
          [9]
          <string-name>
            <surname>Murata</surname>
            <given-names>T.</given-names>
          </string-name>
          :
          <article-title>Petri nets: Properties, analysis and applications</article-title>
          ,
          <source>Proceedings of the IEEE</source>
          , vol.
          <volume>77</volume>
          , no.
          <issue>4</issue>
          ,
          <year>1989</year>
          .
        </mixed-citation>
      </ref>
      <ref id="ref10">
        <mixed-citation>
          [10]
          <string-name>
            <surname>Nitesh</surname>
            <given-names>P.</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Geeta</surname>
            <given-names>R.</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Vijaypal</surname>
            <given-names>S. D.</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Ramesh</surname>
            <given-names>C. P.</given-names>
          </string-name>
          :
          <article-title>Diabetes prediction using artificial neural network, Deep Learning Techniques for Biomedical and Health Informatics</article-title>
          , Academic Press,
          <year>2020</year>
          .
        </mixed-citation>
      </ref>
      <ref id="ref11">
        <mixed-citation>
          [11]
          <string-name>
            <surname>Pashchenko</surname>
            ,
            <given-names>D.</given-names>
          </string-name>
          et al.:
          <article-title>Formal transformation inhibitory safe Petri nets into equivalent not inhibitory</article-title>
          ,
          <source>Procedia Computer Science</source>
          <volume>49</volume>
          (
          <year>2015</year>
          )
          <fpage>99</fpage>
          -
          <lpage>103</lpage>
          .
        </mixed-citation>
      </ref>
      <ref id="ref12">
        <mixed-citation>
          [12]
          <string-name>
            <surname>Prakash</surname>
            <given-names>E. P.</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Srihari</surname>
            <given-names>K.</given-names>
          </string-name>
          ,
          <string-name>
            <given-names>S.</given-names>
            <surname>Karthik</surname>
          </string-name>
          ,
          <string-name>
            <surname>Kamal</surname>
            <given-names>M. V.</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Dileep</surname>
            <given-names>P.</given-names>
          </string-name>
          , Bharath Reddy S.,
          <string-name>
            <surname>Mukunthan</surname>
            <given-names>M. A.</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Somasundaram</surname>
            <given-names>K.</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Jaikumar</surname>
            <given-names>R.</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Gayathri</surname>
            <given-names>N.</given-names>
          </string-name>
          ,
          <string-name>
            <surname>Kibebe</surname>
            <given-names>Sahile</given-names>
          </string-name>
          :
          <article-title>Implementation of Artificial Neural Network to Predict Diabetes with High-Quality Health System</article-title>
          .
          <source>Computational Intelligence and Neuroscience</source>
          , vol.
          <year>2022</year>
          ,
          <string-name>
            <surname>Article</surname>
            <given-names>ID</given-names>
          </string-name>
          1174173,
          <year>2022</year>
          .
        </mixed-citation>
      </ref>
      <ref id="ref13">
        <mixed-citation>
          [13]
          <string-name>
            <surname>Reisig</surname>
            <given-names>W: Petri</given-names>
          </string-name>
          <string-name>
            <surname>Nets. An Introduction</surname>
          </string-name>
          ,
          <source>Part of the book series: Monographs in Theoretical Computer Science</source>
          ,
          <year>1985</year>
          .
        </mixed-citation>
      </ref>
      <ref id="ref14">
        <mixed-citation>
          [14]
          <string-name>
            <surname>Starke</surname>
            <given-names>P</given-names>
          </string-name>
          :
          <string-name>
            <surname>Petri-Netze</surname>
          </string-name>
          ,
          <source>VEB Deutscher Verlag der Wissenschaften</source>
          ,
          <year>1980</year>
          . -
        </mixed-citation>
      </ref>
      <ref id="ref15">
        <mixed-citation>
          [15]
          <string-name>
            <surname>Charlie</surname>
          </string-name>
          , https://www-dssz.informatik.tu-cottbus.de/DSSZ/Software/Charlie
        </mixed-citation>
      </ref>
      <ref id="ref16">
        <mixed-citation>
          [16]
          <string-name>
            <surname>Snoopy</surname>
          </string-name>
          , https://www-dssz.informatik.tu-cottbus.de/DSSZ/Software/Snoopy -
        </mixed-citation>
      </ref>
      <ref id="ref17">
        <mixed-citation>[17] AAPS, https://androidaps.readthedocs.io/en/latest/</mixed-citation>
      </ref>
      <ref id="ref18">
        <mixed-citation>
          [18]
          <string-name>
            <surname>CamAPS</surname>
            <given-names>FX</given-names>
          </string-name>
          , https://camdiab.com/
        </mixed-citation>
      </ref>
      <ref id="ref19">
        <mixed-citation>
          [19]
          <string-name>
            <surname>Diabetes</surname>
            <given-names>Atlas</given-names>
          </string-name>
          , https://diabetesatlas.org/
        </mixed-citation>
      </ref>
      <ref id="ref20">
        <mixed-citation>
          [20]
          <string-name>
            <given-names>International</given-names>
            <surname>Diabetes Federation</surname>
          </string-name>
          , https://federation idf.org
        </mixed-citation>
      </ref>
      <ref id="ref21">
        <mixed-citation>
          [21]
          <string-name>
            <surname>Loop</surname>
          </string-name>
          , https://loopkit.github.io/loopdocs/
        </mixed-citation>
      </ref>
      <ref id="ref22">
        <mixed-citation>
          [22]
          <article-title>MiniMed 780G System</article-title>
          , https://www.medtronic
          <article-title>-diabetes.com/en-gb/minimed-780g-system-info</article-title>
        </mixed-citation>
      </ref>
      <ref id="ref23">
        <mixed-citation>
          [23]
          <string-name>
            <given-names>Tandem</given-names>
            <surname>Tslim Control</surname>
          </string-name>
          <string-name>
            <surname>IQ</surname>
          </string-name>
          , https://www.tandemdiabetes.com/en-gb/home
        </mixed-citation>
      </ref>
      <ref id="ref24">
        <mixed-citation>[24] World Health Organization, https://www.who.int/data/gho/indicator-metadata-registry/imrdetails/2380</mixed-citation>
      </ref>
      <ref id="ref25">
        <mixed-citation>
          [25]
          <string-name>
            <surname>Diabetes</surname>
          </string-name>
          .co.uk, https://www.diabetes.co.uk/
        </mixed-citation>
      </ref>
      <ref id="ref26">
        <mixed-citation>[26] American Diabetes Association, https://diabetes.org/about-diabetes/diagnosis</mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>